# Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

> **NCT01927419** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 142 (actual)

## Conditions studied

- Unresectable Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01927419
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-23
- **Primary completion:** 2014-07-24
- **Final completion:** 2021-02-26
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927419, "Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01927419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*